{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:00:46Z","timestamp":1790712046442,"version":"4.1.0"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Although the advent of enzyme replacement therapy (ERT) for mucopolysaccharidoses (MPS) has paved the way for the treatment for these hereditary disorders, the blood brain barrier (BBB) has prevented patients with MPS involving the central nervous system (CNS) from benefitting from ERT. Therefore, finding ways to increase drug delivery into the brain across the BBB remains a crucial challenge for researchers and clinicians in the field. Attempts have been made to boost brain uptake of enzymes by targeting various receptors (e.g., insulin and transferrin), and several other administration routes have also been tested. This review summarizes the available information on clinical trials (completed, ongoing, and planned) of novel therapeutic agents with efficacy against CNS symptoms in neuropathic MPS and also discusses the common associated challenges and pitfalls, some of which may help elucidate the pathogenesis of the neurodegeneration leading to the manifold CNS symptoms. A summary of current knowledge pertaining to the neuropathological progression and resultant neuropsychiatric manifestations is also provided, because it should be useful to ERT researchers looking for better approaches to treating CNS lesions in MPS.<\/jats:p>","DOI":"10.3390\/ijms21020400","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T03:07:11Z","timestamp":1578539231000},"page":"400","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-8643","authenticated-orcid":false,"given":"Yuji","family":"Sato","sequence":"first","affiliation":[{"name":"Research and Development, JCR Pharmaceuticals, Hyogo 659-0021, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Centre for Lysosomal Storage Diseases, National Centre for Child Health and Development, Tokyo 157-8535, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mehta, A., and Winchester, B. (2012). Current Treatments. Lysosomal Storage Disorders\u2014A Practical Guide, Wiley-Blackwell.","DOI":"10.1002\/9781118514672"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2352-4642(17)30087-1","article-title":"Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS","volume":"2","author":"Giugliani","year":"2018","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-018-0849-8","article-title":"Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): An open label phase 1\u20132 trial","volume":"13","author":"Giuliani","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","article-title":"Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1\/2 Trial","volume":"27","author":"Okuyama","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1038\/s41436-019-0522-1","article-title":"Intrathecal enzyme replacement for Hurler syndrome: Biomarker association with neurocognitive outcomes","volume":"21","author":"Eisengart","year":"2019","journal-title":"Genet. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10545-018-0221-0","article-title":"The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: Heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology","volume":"41","author":"Sohn","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dmcn.13600","article-title":"Treatment strategies for lysosomal storage disorders","volume":"60","author":"Beck","year":"2018","journal-title":"Med. Child Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2017.09.010","article-title":"Practical management of behavioral problems in mucopolysaccharidoses disorders","volume":"122","author":"Escolar","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ymgme.2017.10.006","article-title":"Epilepsy in mucopolysaccharidosis disorders","volume":"122","author":"Scarpa","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_12","unstructured":"Tomtasu, S., Lavery, C., Giugliani, R., Harmatz, P.R., Scarpa, M., Wegrzyn, G., and Orii, T. (2018). Enyme Relacement Therapy for MPS: The Effects and Limitations. Mucopolysaccharidoses Update (2 Volume Set), Nova Science Publishers, Inc."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mehta, A., and Winchester, B. (2012). The Mucopolysaccharidoses. Lysosomal Storage Disorders\u2014A Practical Guide, Wiley-Blackwell.","DOI":"10.1002\/9781118514672"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","article-title":"Treatment of brain disease in the mucopolysaccharidoses","volume":"122","author":"Scarpa","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ymgme.2018.08.003","article-title":"Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders","volume":"125","author":"Bigger","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2741\/4463","article-title":"Glycosaminoglycans and mucopolysaccharidosis type III","volume":"21","author":"Kloska","year":"2016","journal-title":"Front. Biosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/metabo4030655","article-title":"Establishment of glycosaminoglycan assays for mucopolysaccharidoses","volume":"11","author":"Tomatsu","year":"2014","journal-title":"Metabolites"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.mehy.2010.07.044","article-title":"Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?","volume":"75","author":"Narajczyk","year":"2010","journal-title":"Med. Hypotheses"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2017.08.009","article-title":"Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations\u2014Neurological signs and symptoms","volume":"122","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_20","first-page":"87","article-title":"Mechanisms of neurodegeneration in mucopolysaccharidoses","volume":"Volume 1","author":"Tomatsu","year":"2018","journal-title":"Mucopolysaccharidoses Update"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-neuro-080317-061804","article-title":"Lysosomes and Brain Health","volume":"41","author":"Sharma","year":"2018","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2012.07.017","article-title":"Accelerated clinical disease and pathology in mucopolysaccharidosis type IIIB and GalNAc transferase double knockout mice","volume":"107","author":"Mohammed","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_23","first-page":"33","article-title":"Emptying the stores: Lysosomal diseases and therapeutic strategies","volume":"7","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10545-010-9079-5","article-title":"Clinical aspects of neuropathic lysosomal storage disorders","volume":"33","author":"Jardim","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1515\/revneuro-2016-0051","article-title":"New dimensions of connectomics and network plasticity in the central nervous system","volume":"28","author":"Guidolin","year":"2017","journal-title":"Rev. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.neuroscience.2016.12.048","article-title":"Neural plasticity and network remodeling: From concepts to pathology","volume":"344","author":"Cohen","year":"2017","journal-title":"Neuroscience"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1748-1716.1992.tb09370.x","article-title":"Neuronal plasticity and ageing processes in the frame of the \u2018Red Queen Theory\u2019","volume":"145","author":"Agnati","year":"1992","journal-title":"Acta Physiol. Scand."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Dickson, D.W. (2012). Parkinson\u2019s disease and Parkinsonism: Neuropathology. Cold Spring Harb. Perspect. Med., 2.","DOI":"10.1101\/cshperspect.a009258"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/bpa.12426","article-title":"Huntington\u2019s disease (HD): The neuropathology of a multisystem neurodegenerative disorder of the human brain","volume":"26","author":"Seidel","year":"2016","journal-title":"Brain Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-3-662-58081-3","article-title":"P-Tau and Subunit c Mitochondrial ATP Synthase Accumulation in the Central Nervous System of a Woman with Hurler\u2013Scheie Syndrome Treated with Enzyme Replacement Therapy for 12 Years","volume":"Volume 41","author":"Morava","year":"2018","journal-title":"JIMD Reports"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"David, A., Fleminger, S., Kopelman, M., Lovestone, S., and Mellers, J. (2009). Lishman\u2019s Organic Psychiatry: A Textbook of Neuropsychiatry, Wiley-Blackwell. [4th ed.].","DOI":"10.1002\/9781444316803"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8946-1_1","article-title":"An Overview of the Blood-Brain Barrier","volume":"Volume 142","author":"Barichello","year":"2019","journal-title":"Blood-Brain Barrier"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/nan.12010","article-title":"Intracisternal enzyme replacement therapy in lysosomal storage diseases: Dispersal pathways, regional enzyme concentrations and the effect of posttreatment posture","volume":"39","author":"Jolly","year":"2013","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/j.1471-4159.1985.tb07167.x","article-title":"Human blood-brain barrier insulin receptor","volume":"44","author":"Pardridge","year":"1985","journal-title":"J. Neurochem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/JCI119125","article-title":"Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels","volume":"99","author":"Golden","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/jnr.490180206","article-title":"Receptor-mediated transcytosis of transferrin across the blood-brain barrier","volume":"18","author":"Fishman","year":"1987","journal-title":"J. Neurosci. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","article-title":"Transferrin receptor on endothelium of brain capillaries","volume":"312","author":"Jefferies","year":"1984","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/0026-0495(87)90099-0","article-title":"Human blood-brain barrier transferrin receptor","volume":"36","author":"Pardridge","year":"1987","journal-title":"Metabolism"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/bit.25289","article-title":"Insulin receptor antibody-iduronate 2-sulfatase fusion protein: Pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys","volume":"111","author":"Boado","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/dmd.111.042903","article-title":"Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse","volume":"40","author":"Zhou","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13023-017-0635-z","article-title":"Ten years of the Hunter Outcome Survey (HOS): Insights, achievements, and lessons learned from a global patient registry","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_42","unstructured":"(2019, October 03). Available online: https:\/\/denalitherapeutics.com\/investors\/press-release\/denali-therapeutics-receives-orphan-drug-and-rare-pediatric-disease-designation-for-dnl310-and-expands-its-portfolio-of-brain-penetrant-enzyme-replacement-programs."},{"key":"ref_43","unstructured":"(2019, October 03). Available online: http:\/\/www.globalgreencross.com\/newsroom_detail?b_idx=536."},{"key":"ref_44","unstructured":"(2019, October 03). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02262338."},{"key":"ref_45","unstructured":"(2019, October 03). Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03811028."},{"key":"ref_46","unstructured":"(2019, October 03). Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02754076."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2018.12.003","article-title":"Final results of the phase 1\/2, open-label clinical study of intravenous recombinant human N-acetyl-\u03b1-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB","volume":"126","author":"Whitley","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2017.09.007","article-title":"Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses","volume":"122","author":"Shapiro","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): The past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2017.05.004","article-title":"Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: Results of a consensus procedure","volume":"121","author":"Morton","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural progression of neurological disease in mucopolysaccharidosis type II","volume":"27","author":"Holt","year":"2011","journal-title":"Pediatrics"},{"key":"ref_52","unstructured":"US Food and Drug Administration (2019, October 03). Rare Diseases: Common Issues in Drug Development Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-common-issues-drug-development-guidance-industry."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/2\/400\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:42:30Z","timestamp":1760362950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/2\/400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["ijms21020400"],"URL":"https:\/\/doi.org\/10.3390\/ijms21020400","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]}}}